
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a robust performance in the second quarter of 2025, surpassing expectations for both revenue and earnings, and subsequently raising its full-year guidance, which indicates strong operational momentum. Significant growth was noted in the sales of Mounjaro outside the United States, which increased by 60% quarter-over-quarter, fueled by new launches in emerging markets like Brazil, Mexico, and India. Additionally, the introduction of orforglipron as an oral GLP-1 therapy is anticipated to enhance the company’s product offerings, further solidifying its position in the cardiometabolic market.
Bears say
Eli Lilly's stock outlook is negatively impacted by several internal and external factors, including potential pricing and rebate pressures that could affect revenue generation across its key products. The company has experienced a disappointing prescription trajectory for its tirzepatide product, Mounjaro, alongside observed declines in Zepbound prescriptions, which are anticipated to hinder volumetric growth in the upcoming quarter. Additionally, the competitive threat posed by orforglipron, particularly in the cardiometabolic segment, along with reduced peak sales forecasts and concerns over its launch performance, contributes further to a pessimistic financial outlook for Eli Lilly.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares